PHASE IB STUDY TO DEFINE THE OPTIMAL LOW DOSE OF NGR-HTNF, A NOVEL VASCULAR TARGETING AGENT (VTA), IN COMBINATION WITH CISPLATIN IN PATIENTS (PTS) WITH SOLID TUMOURS

被引：0
|
作者：
Gregorc, V. [1 ]
De Braud, F. G. [2 ]
De Pas, T. M. [3 ]
Citterio, G. [1 ]
Scalamogna, R. [3 ]
Boselli, S. [3 ]
Giovannini, M. [1 ]
Caligaris-Cappio, F. [1 ]
Lambiase, A. [4 ]
Bordignon, C. [4 ]
机构：
[1] Ist Sci San Raffaele, Dept Oncol, Milan, Italy
[2] Ist Europeo Oncol, New Drugs Dev Unit, Milan, Italy
[3] Ist Europeo Oncol, Dept Oncol, Milan, Italy
[4] MolMed, Clin Dept, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：160 / 160
页数：1
相关论文
共 50 条
  • [1] A phase I study to define the optimal low dose of NGR-hTNF, a novel vascular targeting agent (VTA), in combination with cisplatin in patients (pts) with solid tumors
    De Braud, F. G.
    Gregorc, V.
    De Pas, T. M.
    Citterio, G.
    Scalamogna, R.
    Boselli, S.
    Giovannini, M.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Phase I study of NGR-hTNF, a vascular targeting agent (VTA), in combination withcisplatin in refractory patients (pts) with solid tumours
    Citterio, G.
    De Braud, F. G.
    Gregorc, V.
    De Pas, T. M.
    Noberasco, C.
    Boselli, S.
    Giovannini, M.
    Cappio, F. Caligaris
    Lambiase, A.
    Bordignon, C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 129 - 129
  • [3] Phase Ib study of NGR-hTNF, a selective vascular targeting agent (VTA), in combination with cisplatin in patients with refractory solid tumors
    Citterio, G.
    De Braud, F. G.
    Gregorc, V.
    De Pas, T. M.
    Scalamogna, R.
    Boselli, S.
    Giovannini, M.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours
    Gregorc, V.
    Santoro, A.
    Bennicelli, E.
    Punt, C. J. A.
    Citterio, G.
    Timmer-Bonte, J. N. H.
    Cappio, F. Caligaris
    Lambiase, A.
    Bordignon, C.
    van Herpen, C. M. L.
    BRITISH JOURNAL OF CANCER, 2009, 101 (02) : 219 - 224
  • [5] A phase II study of NGR-hTNF, a novel vascular targeting agent (VTA), administered as single agent at low dose in pretreated patients (pts) with advanced hepatocellular carcinoma (HCC)
    Citterio, G.
    Santoro, A.
    Scalamogna, R.
    Pressiani, T.
    Gregorc, V.
    Rossoni, G.
    Donadoni, G.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors
    Gregorc, Vanesa
    De Braud, Filippo G.
    De Pas, Tommaso M.
    Scalamogna, Roberto
    Citterio, Giovanni
    Milani, Alessandra
    Boselli, Sabrina
    Catania, Chiara
    Donadoni, Giovanni
    Rossoni, Gilda
    Ghio, Domenico
    Spitaleri, Gianluca
    Ammannati, Cristina
    Colombi, Scialini
    Caligaris-Cappio, Federico
    Lambiase, Antonio
    Bordignon, Claudio
    CLINICAL CANCER RESEARCH, 2011, 17 (07) : 1964 - 1972
  • [7] Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours
    Gregorc, Vanesa
    Citterio, Giovanni
    Vitali, Giordano
    Spreafico, Anna
    Scifo, Paola
    Borri, Anna
    Donadoni, Giovanni
    Rossoni, Gilda
    Corti, Angelo
    Caligaris-Cappio, Federico
    Del Maschio, Alessandro
    Esposito, Antonio
    De Cobelli, Francesco
    Dell'Acqua, Flavio
    Troysi, Antonella
    Bruzzi, Paolo
    Lambiase, Antonio
    Bordignon, Claudio
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (01) : 198 - 206
  • [8] A phase II study of NGR-hTNF, a novel vascular targeting agent (VTA), administered as single agent at low dose in patients (pts) with colorectal cancer (CRC) refractory to standard regimens
    Santoro, A.
    Andretta, V.
    Gregorc, V.
    Rimassa, L.
    Bennicelli, E.
    Sclafani, F.
    Caprioni, F.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] PHASE II STUDY OF NGR-HTNF, A NOVEL VASCULAR TARGETING AGENT (VTA), ADMINISTERED AS SINGLE AGENT AT LOW DOSE IN PATIENTS (PTS) WITH COLORECTAL CANCER (CRC) REFRACTORY TO STANDARD REGIMENS
    Rimassa, L.
    Sobrero, A.
    Santoro, A.
    Andretta, V.
    Gregorc, V.
    Sclafani, F.
    Caprioni, F.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 136 - 136
  • [10] Phase Ib study of NGR–hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours
    V Gregorc
    A Santoro
    E Bennicelli
    C J A Punt
    G Citterio
    J N H Timmer-Bonte
    F Caligaris Cappio
    A Lambiase
    C Bordignon
    C M L van Herpen
    British Journal of Cancer, 2009, 101 : 219 - 224
12345